Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011

INTRODUCTION: Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor available in France since 2006, is indicated for the treatment of HIV-1 infection in combination with a ritonavir boosted protease inhibitor (PI) in antiretroviral treatment-experienced adult patients. To assess its imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacombe, Jean-Marc, Goujard, Cecile, Valantin, Marc-Antoine, Cheret, Arnaud, Lahoulou, Rima, Girard, Pierre-Marie, Costagliola, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P249
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225403/
https://www.ncbi.nlm.nih.gov/pubmed/25397525
http://dx.doi.org/10.7448/IAS.17.4.19781

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225403/
https://www.ncbi.nlm.nih.gov/pubmed/25397525
http://dx.doi.org/10.7448/IAS.17.4.19781

Ejemplares similares